Format

Send to

Choose Destination
Alzheimers Dement. 2012 Jan;8(1):65-73. doi: 10.1016/j.jalz.2011.07.004. Epub 2011 Nov 2.

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative.

Author information

1
Innogenetics NV, Ghent, Belgium.

Abstract

BACKGROUND:

Numerous studies show that the cerebrospinal fluid biomarkers total tau (T-tau), tau phosphorylated at threonine 181 (P-tau(181P)), and amyloid-β (1-42) (Aβ(1-42)) have high diagnostic accuracy for Alzheimer's disease. Variability in concentrations for Aβ(1-42), T-tau, and P-tau(181P) drives the need for standardization.

METHODS:

Key issues were identified and discussed before the first meeting of the members of the Alzheimer's Biomarkers Standardization Initiative (ABSI). Subsequent ABSI consensus meetings focused on preanalytical issues.

RESULTS:

Consensus was reached on preanalytical issues such as the effects of fasting, different tube types, centrifugation, time and temperature before storage, storage temperature, repeated freeze/thaw cycles, and length of storage on concentrations of Aβ(1-42), T-tau, and P-tau(181P) in cerebrospinal fluid.

CONCLUSIONS:

The consensus reached on preanalytical issues and the recommendations put forward during the ABSI consensus meetings are presented in this paper.

PMID:
22047631
DOI:
10.1016/j.jalz.2011.07.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center